bruising at tirzepatide injection site Weekly weight injections can cause reactions and even allergic responses. Here's what to know Injection Site Bruising After Tirzepatide:

The Journal of Clinical Investigation, 79 (2), 616619

FDA Submission Timeline Based on the TRIUMPH-4 success and expected 2026 readouts, analysts predict: Late 2026: Completion of core TRIUMPH trials Q4 2026 or Q1 2027: New Drug Application (NDA) submission to FDA Mid to Late 2027: Potential FDA approval Early 2028: Commercial launch Eli Lilly has not officially confirmed these timelines, but the company has indicated it will submit for regulatory approval once sufficient Phase 3 data is available

Some involved severe hypoglycemia so dangerous that patients needed emergency treatment

Ask specifically: what are your coverage criteria for Wegovy, Zepbound, or whatever GLP-1 medication you are pursuing

Safety Comparison Table# Research Evidence Comparison# MariTide Research# MariTide's key evidence comes from a phase 2 trial published in the New England Journal of Medicine (2025): Design: 592 participants across two cohorts -- obesity without T2D, and obesity with T2D -- over 52 weeks Obesity cohort: Mean weight loss ranged from -12.3% to -16.2% with MariTide vs -2.5% with placebo (up to 20% in some analyses) Obesity + T2D cohort: Mean weight loss ranged from -8.4% to -12.3% with MariTide vs -1.7% with placebo